The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
Glioblastoma multiforme: Pathogenesis and treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Curran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., & Ruiz i Altaba, A. (2007) · Current Biology · doi:10.1016/j.cub.2006.11.033 · Cited by 1,050
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Epidemiology and molecular pathology of glioma
Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., & Wrensch, M. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0289 · Cited by 949
Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth
Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J. K., Fang, X., Sloan, A. E., Mao, Y., Lathia, J. D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.02.021 · Cited by 905
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Epidemiology of primary brain tumors: Current concepts and review of the literature
Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.278 · Cited by 837
Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 829
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Metabolic Modulation of Glioblastoma with Dichloroacetate
Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E., Maguire, C., Gammer, T.-L., Mackey, J. R., Fulton, D., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000677 · Cited by 720
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2012) · Glia · doi:10.1002/glia.21264 · Cited by 712
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma
Liu, C., Sage, J. C., Miller, M. R., Verhaak, R. G. W., Hippenmeyer, S., Vogel, H., Foreman, O., Bronson, R. T., Nishiyama, A., Luo, L., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.014 · Cited by 692
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Integrin Alpha 6 Regulates Glioblastoma Stem Cells
Lathia, J. D., Gallagher, J., Heddleston, J. M., Wang, J., Eyler, C. E., MacSwords, J., Wu, Q., Vasanji, A., McLendon, R. E., Hjelmeland, A. B., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.02.018 · Cited by 660
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Louis, D. N. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100043 · Cited by 648
Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma
Bar, E. E., Chaudhry, A., Lin, A., Fan, X., Schreck, K., Matsui, W., Piccirillo, S., Vescovi, A. L., DiMeco, F., Olivi, A., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0166 · Cited by 607
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
VEGF as a Therapeutic Target in Cancer
Ferrara, N. (2005) · Oncology · doi:10.1159/000088479 · Cited by 578
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
Mani, A., & Gelmann, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.081 · Cited by 549
Fisher, J. L., Schwartzbaum, J. A., Wrensch, M., & Wiemels, J. L. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.002 · Cited by 528
Peñuelas, S., Anido, J., Prieto-Sánchez, R. M., Folch, G., Barba, I., Cuartas, I., García-Dorado, D., Poca, M. A., Sahuquillo, J., Baselga, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.011 · Cited by 526
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth
Bao, S., Wu, Q., Li, Z., Sathornsumetee, S., Wang, H., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1079 · Cited by 427
Sb, G., Byar, D. P., Walker, Pistenmaa, D. A., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., Mealey, J., Gl, O., et al. (1983) · PubMed · Cited by 404
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
c-MET as a potential therapeutic target and biomarker in cancer
Sierra, J. R., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422557 · Cited by 365
Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 358
Stupp, R., Tonn, J.-C., Brada, M., & Pentheroudakis, G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq187 · Cited by 348
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Glioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
Östman, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.002 · Cited by 326
Molecularly targeted therapy for malignant glioma
Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., & Rich, J. N. (2007) · Cancer · doi:10.1002/cncr.22741 · Cited by 325
Scott Ph.D., C. B., Scarantino M.D., P. D., Urtasun M.D., Movsas M.D., Jones M.D., Simpson M.D., Fischbach M.D., & Curran Jr., M. D. (1998) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00485-9 · Cited by 323
Monoclonal antibodies as therapeutic agents for cancer
Harris, M. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01467-6 · Cited by 320
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Hussain, S. F., Kong, L.-Y., Jordan, J., Conrad, C., Madden, T., Fokt, I., Priebe, W., & Heimberger, A. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1243 · Cited by 314
A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo
Martens, T., Schmidt, N.-O., Eckerich, C., Fillbrandt, R., Merchant, M., Schwall, R., Westphal, M., & Lamszus, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1418 · Cited by 305
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 299
Glutamate and the biology of gliomas
de Groot, J., & Sontheimer, H. (2011) · Glia · doi:10.1002/glia.21113 · Cited by 293
Jiang, H., Gomez-Manzano, C., Aoki, H., Alonso, M. M., Kondo, S., McCormick, F., Xu, J., Kondo, Y., Bekele, B. N., Colman, H., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm102 · Cited by 278
Møller, H. G., Rasmussen, A. P., Andersen, H. H., Johnsen, K. B., Henriksen, M., & Duroux, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8349-7 · Cited by 266
Guryanova, O. A., Wu, Q., Cheng, L., Lathia, J. D., Huang, Z., Yang, J., MacSwords, J., Eyler, C. E., McLendon, R. E., Heddleston, J. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.004 · Cited by 260
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J.-F., D'Hondt, L., Strauven, T., Chaskis, C., In't Veld, P., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 250
Zhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1212 · Cited by 249
C. Potts, B., X. Albitar, M., C. Anderson, K., Baritaki, S., Berkers, C., Bonavida, B., Chandra, J., Chauhan, D., C. Cusack, J., Fenical, W., et al. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519716 · Cited by 243
L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth
Schmid, R. S., & Maness, P. F. (2008) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2008.07.015 · Cited by 235
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 232
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 231
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1636 · Cited by 228
Raymond, E., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P. M. J., Frenay, M., Rampling, R., Stupp, R., Kros, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9235 · Cited by 227
Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer
Sheppard, K., Kinross, K. M., Solomon, B., Pearson, R. B., & Phillips, W. A. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.60 · Cited by 225
Iwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
Friday, B. B., Anderson, S. K., Buckner, J., Yu, C., Giannini, C., Geoffroy, F., Schwerkoske, J., Mazurczak, M., Gross, H., Pajon, E., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor198 · Cited by 213
Long-term use of cellular phones and brain tumours: increased risk associated with use for ⩾10 years
Hardell, L., Carlberg, M., Söderqvist, F., Mild, K. H., & Morgan, L. L. (2007) · Occupational and Environmental Medicine · doi:10.1136/oem.2006.029751 · Cited by 213
Thiessen, B., Stewart, C., Tsao, M., Kamel-Reid, S., Schaiquevich, P., Mason, W., Easaw, J., Belanger, K., Forsyth, P., McIntosh, L., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1041-6 · Cited by 209
Reardon, D. A., Nabors, L. B., Stupp, R., & Mikkelsen, T. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1225 · Cited by 206
Temozolomide in malignant gliomas: current use and future targets
Villano, J. L., Seery, T. E., & Bressler, L. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1050-5 · Cited by 202
Medical management of patients with brain tumors
Wen, P. Y., Schiff, D., Kesari, S., Drappatz, J., Gigas, D. C., & Doherty, L. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9193-2 · Cited by 191
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., Sathornsumetee, S., Herndon, J. E., Dowell, J. M., McLendon, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2215 · Cited by 191
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Curcumin promotes differentiation of glioma‐initiating cells by inducing autophagy
Zhuang, W., Long, L., Zheng, B., Ji, W., Yang, N., Zhang, Q., & Liang, Z. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02198.x · Cited by 188
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
Glass, J., Hochberg, F. H., Gruber, M. L., et al. (1992) · Journal of neurosurgery · doi:10.3171/jns.1992.76.5.0741 · Cited by 187
Berdelle, N., Nikolova, T., Quiros, S., Efferth, T., & Kaina, B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0534 · Cited by 181
Carbon Nanotubes Enhance CpG Uptake and Potentiate Antiglioma Immunity
Zhao, D., Alizadeh, D., Zhang, L., Liu, W., Farrukh, O., Manuel, E., Diamond, D. J., & Badie, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2444 · Cited by 181
Chinot, O.-L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.-M., & Grisoli, F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2449 · Cited by 179
Pelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
Clarke, J. L., Iwamoto, F. M., Sul, J., Panageas, K., Lassman, A. B., DeAngelis, L. M., Hormigo, A., Nolan, C. P., Gavrilovic, I., Karimi, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7944 · Cited by 179
Momota, H., Nerio, E., & Holland, E. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1042 · Cited by 177
Wen, P. Y., Schiff, D., Cloughesy, T. F., Raizer, J. J., Laterra, J., Smitt, M., Wolf, M., Oliner, K. S., Anderson, A., Zhu, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq198 · Cited by 173
Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
Butowski, N. A., Sneed, P. K., & Chang, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7522 · Cited by 172
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172
Grossman, S. A., Ye, X., Chamberlain, M., Mikkelsen, T., Batchelor, T., Desideri, S., Piantadosi, S., Fisher, J., & Fine, H. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6895 · Cited by 172
Koul, D., Fu, J., Shen, R., LaFortune, T. A., Wang, S., Tiao, N., Kim, Y.-W., Liu, J.-L., Ramnarian, D., Yuan, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1558 · Cited by 171
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
Jabbour, E. J., & Kantarjian, H. M. (2012) · American Journal of Hematology · doi:10.1002/ajh.23282 · Cited by 169
Anticancer Effects of Niclosamide in Human Glioblastoma
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2895 · Cited by 168
Kast, R. E., Boockvar, J. A., Brüning, A., Cappello, F., Chang, W.-W., Cvek, B., Dou, Q. P., Duenas-Gonzalez, A., Efferth, T., Focosi, D., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.969 · Cited by 167
Hsu, J. Y., & Wakelee, H. A. (2009) · BioDrugs · doi:10.2165/11317600-000000000-00000 · Cited by 165
Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 165
Fouladi, M., Stewart, C. F., Olson, J., Wagner, L. M., Onar-Thomas, A., Kocak, M., Packer, R. J., Goldman, S., Gururangan, S., Gajjar, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7806 · Cited by 164
Linnet, K., & Ejsing, T. B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.06.003 · Cited by 163
Farrell, C. J., & Plotkin, S. R. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.008 · Cited by 162
Therapeutic targeting in the estrogen receptor hormonal pathway
Katzenellenbogen, B. S., & Frasor, J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.004 · Cited by 159
Joensuu, H., Puputti, M., Sihto, H., Tynninen, O., & Nupponen, N. N. (2005) · The Journal of Pathology · doi:10.1002/path.1823 · Cited by 158
Dresemann, G. P., Weller, M., Rosenthal, M. A., Wedding, U., Wagner, W., Engel, E., Heinrich, B., Mayer‐Steinacker, R., Krarup‐Hansen, A., Fluge, Ø., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9976-3 · Cited by 156
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas
Knobbe-Thomsen, C. B., REIFENBERGER, J., & Reifenberger, G. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0929-9 · Cited by 156
Cloughesy, T. F., Wen, P. Y., Robins, H. I., Chang, S. M., Groves, M. D., Fink, K., Junck, L., Schiff, D., Abrey, L. E., Gilbert, M. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2323 · Cited by 154
Treatment of high-grade glioma in children and adolescents
MacDonald, T. J., Aguilera, D., & Kramm, C. M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor092 · Cited by 154
Kitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0560 · Cited by 151
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
Sauvageot, C., Weatherbee, J. L., Kesari, S., Winters, S. E., Barnes, J. W., DellaGatta, J. L., Ramakrishna, N. R., Stiles, C. D., Kung, A. L., Kieran, M. W., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-060 · Cited by 145
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wick, W., Weller, M., Weiler, M., Batchelor, T. T., Yung, A. W. K., & Platten, M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor039 · Cited by 145
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N. N., Michotte, A., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0402-7 · Cited by 144
Reardon, D. A., Dresemann, G. P., Taillibert, S., Campone, M., van den Bent, M. J., Clément, P. M., Blomquist, E., Gordower, L., Schultz, H., Raizer, J. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 141
Gilbert, M. R., Kuhn, J., Lamborn, K. R., Lieberman, F. S., Wen, P. Y., Mehta, M. P., Cloughesy, T. F., Lassman, A. B., DeAngelis, L. M., Chang, S. M., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0650-1 · Cited by 140
Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
Ahluwalia, M. S., de Groot, J., Liu, W., & Gladson, C. L. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.014 · Cited by 139
Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., Marcello, J. E., Herndon, J. E., McLendon, R. E., Janney, D., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0217-6 · Cited by 138
Buchanan, S. G., Hendle, J., Lee, P. S., Smith, C. R., Bounaud, P., Jessen, K., Tang, C. M., Huser, N. H., Felce, J. D., Froning, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0477 · Cited by 135
Nabors, B., Mikkelsen, T., Hegi, M. E., Ye, X., Batchelor, T. T., Lesser, G. J., Peereboom, D. M., Rosenfeld, M. R., Olsen, J., Brem, S., et al. (2012) · Cancer · doi:10.1002/cncr.27585 · Cited by 132
Reardon, D. A., Groves, M. D., Wen, P. Y., Nabors, B., Mikkelsen, T., Rosenfeld, S., Raizer, J. J., Barriuso, J., McLendon, R. E., Suttle, A. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1707 · Cited by 132
Hainsworth, J. D., Ervin, T. J., Friedman, E. K., Priego, V. M., Murphy, P. B., Clark, B. L., & Lamar, R. E. (2010) · Cancer · doi:10.1002/cncr.25275 · Cited by 131
Okada, H., Lieberman, F. S., Walter, K. A., Lunsford, L. D., Kondziolka, D. S., Bejjani, G. K., Hamilton, R. L., Torres-Trejo, A., Kaliński, P., Cai, Q., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-67 · Cited by 130
Gan, H. K., Šeruga, B., & Knox, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902980171 · Cited by 129
Glioblastoma cells: A heterogeneous and fatal tumor interacting with the parenchyma
Alves, T. R., Lima, F. R. S., Kahn, S. A., Lobo, D. S., Dubois, L. G., Soletti, R. C., Borges, H. L., & Moura‐Neto, V. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.04.022 · Cited by 128
Xie, Q. R., Bradley, R., Kang, L., Koeman, J. M., Ascierto, M. L., Worschech, A., Giorgi, V. D., Wang, E., Kefene, L., Su, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119059109 · Cited by 128
IWAMOTO, F. M., Lamborn, K. R., Kuhn, J. G., Wen, P. Y., Yung, W. K. A., Gilbert, M. R., Chang, S. M., Lieberman, F. S., Prados, M. D., & Fine, H. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor017 · Cited by 126
Gaspar, N., Sharp, S. Y., Pacey, S., Jones, C., Walton, M. I., Vassal, G., Eccles, S. A., Pearson, A. D. J., & Workman, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3131 · Cited by 124
IWAMOTO, F. M., Kreisl, T. N., Kim, L., Duic, J. P., Butman, J. A., Albert, P. S., & Fine, H. A. (2010) · Cancer · doi:10.1002/cncr.24957 · Cited by 123
Terasaki, M., Shibui, S., Narita, Y., Fujimaki, T., Aoki, T., Kajiwara, K., Sawamura, Y., Kurisu, K., Mineta, T., Yamada, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7499 · Cited by 121
Targeting the c-Met Pathway Potentiates Glioblastoma Responses to γ-Radiation
Lal, B., Xia, S., Abounader, R., & Laterra, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0166 · Cited by 120
Advances in the Treatment of Malignant Gliomas
Khasraw, M., & Lassman, A. B. (2010) · Current Oncology Reports · doi:10.1007/s11912-009-0077-4 · Cited by 119
di Tomaso, E., London, N. R., Fuja, D. G., Logie, J. J., Tyrrell, J. A., Kamoun, W. S., Munn, L. L., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005123 · Cited by 116
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
Kreisl, T. N., Kotliarova, S. E., Butman, J. A., Albert, P. S., Kim, L., Musib, L. C., Thornton, D., & Fine, H. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop042 · Cited by 116
Fu, J., Rodova, M., Nanta, R., Meeker, D., Veldhuizen, P. J. V., Srivastava, R. K., & Shankar, S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not011 · Cited by 112
Razis, E. D., Selviaridis, P., Labropoulos, S., Norris, J. L., Zhu, M. J., Song, D. D., Kalebic, T., Torrens, M. J., Kalogera‐Fountzila, A., Karkavelas, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1867 · Cited by 110
Chi, A. S., Batchelor, T. T., Kwak, E. L., Clark, J. W., Wang, D. L., Wilner, K. D., Louis, D. N., & Iafrate, A. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4586 · Cited by 110
Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma
Dillman, R. O., Duma, C., Ellis, R. A., Cornforth, A. N., Schiltz, P. M., Sharp, S. L., & DePriest, C. B. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b2910f · Cited by 109
Peereboom, D. M., Ahluwalia, M. S., Ye, X., Supko, J. G., Hilderbrand, S. L., Phuphanich, S., Nabors, B., Rosenfeld, M. R., Mikkelsen, T., & Grossman, S. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos322 · Cited by 109
Choi, B. D., Suryadevara, C. M., Gedeon, P. C., Herndon, J. E., Sanchez-Perez, L. A., Bigner, D. D., & Sampson, J. H. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.03.012 · Cited by 108
Lun, X., Alain, T., Zemp, F. J., Zhou, H., Rahman, M. M., Hamilton, M. G., McFadden, G., Bell, J. C., Senger, D. L., & Forsyth, P. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1510 · Cited by 106
Targeting integrins in malignant glioma
Tabatabai, G., Weller, M., Nabors, B., Picard, M. A., Reardon, D. A., Mikkelsen, T., Rüegg, C., & Stupp, R. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0156-3 · Cited by 104
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
Welsh, J. W., Mahadevan, D., Ellsworth, R., Cooke, L. S., Bearss, D. J., & Stea, B. (2009) · Radiation Oncology · doi:10.1186/1748-717x-4-69 · Cited by 104
VEGF Trap induces antiglioma effect at different stages of disease
Gomez‐Manzano, C., Holash, J. A., Fueyo-Margareto, J., Xu, J., Conrad, C. A., Aldape, K., de Groot, J. F., Bekele, B. N., & Yung, W. K. A. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-061 · Cited by 103
Baltuch, G. H., Couldwell, W. T., Villemure, J., & Yong, V. W. (1993) · Neurosurgery · doi:10.1227/00006123-199309000-00021 · Cited by 100
Farnesyltransferase inhibitors
Sebti, S. M., & Adjei, A. A. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.012 · Cited by 100
Fakhrai, H., Mantil, J., Liu, L., Nicholson, G. L., Murphy-Satter, C. S., Ruppert, J. M., & Shawler, D. L. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700975 · Cited by 99
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma
Nagane, M., Nishikawa, R., Narita, Y., Kobayashi, H., Takano, S., Shinoura, N., Aoki, T., Sugiyama, K., Kuratsu, J., Muragaki, Y., et al. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys121 · Cited by 99
Reardon, D. A., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., Rich, J. N., McLendon, R. E., Herndon, J. E., Marcello, J. E., Threatt, S., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0403-6 · Cited by 98
Agarwal, S., Mittapalli, R. K., Zellmer, D. M., Gallardo, J. L., Donelson, R., Seiler, C., Decker, S. A., SantaCruz, K. S., Pokorny, J. L., Sarkaria, J. N., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0552 · Cited by 98
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
Kreisl, T. N., McNeill, K. A., Sul, J., Iwamoto, F. M., Shih, J. H., & Fine, H. A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos265 · Cited by 96
Zhang, M., Herion, T., Timke, C., Han, N., Hauser, K., Weber, K. J., Peschke, P., Wirkner, U., Lahn, M., & Huber, P. E. (2011) · Neoplasia · doi:10.1593/neo.11258 · Cited by 94
Reardon, D. A., Egorin, M. J., Desjardins, A., Vredenburgh, J. J., Beumer, J. H., Lagattuta, T. F., Gururangan, S., Herndon, J. E., Salvado, A. J., & Friedman, H. S. (2009) · Cancer · doi:10.1002/cncr.24213 · Cited by 91
PCV chemotherapy for recurrent glioblastoma
Schmidt, F., Fischer, J., Herrlinger, U., Dietz, K., DICHGANS, J., & Weller, M. (2006) · Neurology · doi:10.1212/01.wnl.0000197792.73656.c2 · Cited by 89
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma
Phuphanich, S., Supko, J. G., Carson, K. A., Grossman, S. A., Nabors, B., Mikkelsen, T., Lesser, G. J., Rosenfeld, S., Desideri, S., & Olson, J. J. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0143-7 · Cited by 89
Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion
Deborah, H., Lewis‐Tuffin, L. J., Carlson, B. L., Schroeder, M. A., Rodríguez, F. J., Giannini, C., Galanis, E., Sarkaria, J. N., & Anastasiadis, P. Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056505 · Cited by 89
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
Pan, E., Yu, D., Yue, B., Potthast, L., Chowdhary, S. A., Smith, P. S., & Chamberlain, M. C. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0943-z · Cited by 87
E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
Glen, H., Mason, S. M., Patel, H., MacLeod, K. G., & Brunton, V. G. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-309 · Cited by 86
Sarkaria, J. N., Galanis, E., Wu, W., Peller, P. J., Giannini, C., Brown, P. D., Uhm, J. H., McGraw, S. C., Jaeckle, K. A., & Buckner, J. C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.064 · Cited by 85
Nivolumab: A Review of Its Use in Patients with Malignant Melanoma
Deeks, E. D. (2014) · Drugs · doi:10.1007/s40265-014-0234-4 · Cited by 85
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
Kang, T. Y., Jin, T., Elinzano, H., & Peereboom, D. M. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9599-0 · Cited by 85
Hainsworth, J. D., Shih, K. C., Shepard, G. C., Tillinghast, G. W., Brinker, B. T., & Spigel, D. R. (2012) · PubMed · Cited by 84
Efferth, T., Ramírez, T., Gebhart, E., & Halatsch, M. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.12.035 · Cited by 83
Krebs, S. S., Chow, K. K. H., Yi, Z., Rodríguez-Cruz, T., Hegde, M. G., Gerken, C. P., Ahmed, N. M., & Gottschalk, S. M. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.02.012 · Cited by 83
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
Drappatz, J., Lee, E. Q., Hammond, S., Grimm, S. A., Norden, A. D., Beroukhim, R., Gerard, M., Schiff, D., S., A., Batchelor, T. T., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0717-z · Cited by 81
Sawada, M., Imai, F., Suzuki, H., Hayakawa, M., Kanno, T., & Nagatsu, T. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00879-5 · Cited by 81
Solomón, M. T., Selva, J. C., Figueredo, J., Vaquer, J., Toledo, C., Quintanal, N., Salva, S., Domíngez, R., Alert, J., Marinello, J. J., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-299 · Cited by 80
Sarkaria, J. N., Galanis, E., Wu, W., Dietz, A. B., Kaufmann, T. J., Gustafson, M. P., Brown, P. D., Uhm, J. H., Rao, R. D., Doyle, L. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1453 · Cited by 79
Butowski, N. A., Lamborn, K. R., Lee, B. L., Prados, M. D., Cloughesy, T. F., DeAngelis, L. M., Abrey, L. E., Fink, K., Lieberman, F. S., Mehta, M. P., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9705-3 · Cited by 79
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy
Liu, G., Akasaki, Y., Khong, H. T., Wheeler, C. J., Das, A., Black, K. L., & Yu, J. S. (2005) · Oncogene · doi:10.1038/sj.onc.1208519 · Cited by 78
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
Shen, J., Zheng, H., Ruan, J., Fang, W., Li, A., Tian, G., Niu, X., Luo, S., & Zhao, P. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.306 · Cited by 77
Brandes, A. A., Stupp, R., Hau, P., Lacombe, D., Gorlia, T., Tosoni, A., Mirimanoff, R. O., Kros, J. M., & van den Bent, M. J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.10.029 · Cited by 77
Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas
Fitz, C. D. V., Li, G., & Wong, A. J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.177 · Cited by 77
Butowski, N. A., Chang, S. M., Lamborn, K. R., Polley, M.-Y., Pieper, R. O., Costello, J., VandenBerg, S. R., Parvataneni, R., Nicole, A., Sneed, P. K., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor130 · Cited by 77
Koso, H., Takeda, H., Yew, C. C. K., Ward, J. M., Nariai, N., Ueno, K., Nagasaki, M., Watanabe, S., Rust, A. G., Adams, D. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215899109 · Cited by 74
Dixit, D., Sharma, V., Ghosh, S., Koul, N., Mishra, P. K., & Sen, E. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.031 · Cited by 73
Pitter, K. L., Galbán, C. J., Galbán, S., Tehrani, O. S., Li, F., Charles, N. A., Bradbury, M. S., Becher, O. J., Chenevert, T. L., Rehemtulla, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014545 · Cited by 73
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
Reardon, D. A., Vredenburgh, J. J., Sykes, A. D., Desjardins, A., Peters, K. B., Gururangan, S., Sathornsumetee, S., Rich, J. N., Herndon, J. E., & Friedman, H. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0631-4 · Cited by 72
EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism
Pines, G., Huang, P. H., Zwang, Y., White, F. M., & Yarden, Y. (2010) · Oncogene · doi:10.1038/onc.2010.313 · Cited by 71
A Review of Novel Therapies for Melanoma
Karimkhani, C., Gonzalez, R. C., & Dellavalle, R. P. (2014) · American Journal of Clinical Dermatology · doi:10.1007/s40257-014-0083-7 · Cited by 71
Sai, K., Wang, S., Balasubramaniyan, V., Conrad, C. A., Lang, F. F., Aldape, K., Szymański, S., Fokt, I., Dasgupta, A., Madden, T. L., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0786-z · Cited by 71
Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors
Haas-Kogan, D. A., Prados, M. D., Lamborn, K. R., Tihan, T., Berger, M. S., & Stokoe, D. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2105 · Cited by 70
A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors
Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., Tohnya, T. M., Figg, W. D., & Royce, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1546 · Cited by 69
Lv, S., Teugels, E., Sadones, J., Brakeleer, S. D., Duerinck, J., Four, S. D., Michotte, A., Grève, J. D., & Neyns, B. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1539 · Cited by 67
Wang, K., Pan, L., Che, X., Cui, D., & Li, C. (2010) · Neurological Research · doi:10.1179/016164110x12681290831360 · Cited by 67
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
Lu‐Emerson, C., Norden, A. D., Drappatz, J., Lee, E. Q., Beroukhim, R., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Ruland, S. F., & Wen, P. Y. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0489-x · Cited by 66
Shah, G., Loizos, N., Youssoufian, H., Schwartz, J. D., & Rowinsky, E. K. (2010) · Cancer · doi:10.1002/cncr.24788 · Cited by 65
Glioblastoma Cancer Stem-Like Cells: Implications for Pathogenesis and Treatment
Nduom, E. K.-E., Hadjipanayis, C. G., & Meir, E. G. V. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182452e0d · Cited by 65
Fukai, J., Nishio, K., Itakura, T., & Koizumi, F. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00945.x · Cited by 64
Cited by
Glioblastoma: Overview of Disease and Treatment
Davis, M. (2016) · Clinical Journal of Oncology Nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,205
Current and future strategies for treatment of glioma
Bush, N. A. O., Chang, S. M., & Berger, M. S. (2017) · Neurosurgical Review · doi:10.1007/s10143-016-0709-8 · Cited by 577
Israel, L. L., Galstyan, A., Holler, E., & Ljubimova, J. Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.009 · Cited by 337
Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153550 · Cited by 330
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Kramer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 320
Metadata
- Authors
- Alifieris, C., & Trafalis, D. T.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 152
- Pages
- 63-82
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1998941426
- Cited by
- 820
- References
- 265
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.